SCHEMBL1991348

SCHEMBL1991348

O=C(O)c1ccccc1C(=O)Nc1ccccc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 1.00
CYP3A4 P08684 1/20 0.75
CYP2C9 P11712 1/20 0.75
ALOX12 P18054 1/20 0.75
MEN1 O00255 6/20 0.69
KMT2A Q03164 6/20 0.69
HPGD P15428 2/20 0.68
HTT P42858 2/20 0.68
KDM4E B2RXH2 1/20 0.68
LMNA P02545 1/20 0.68
TP53 P04637 1/20 0.68
HSD17B10 Q99714 1/20 0.68
TDP1 Q9NUW8 2/20 0.66
CYP1A2 P05177 1/20 0.64
METAP2 P50579 1/20 0.63
CHRNB2 P17787 1/20 0.63
CHRNB4 P30926 1/20 0.63
CHRNA3 P32297 1/20 0.63
CHRNA4 P43681 1/20 0.63
GFER P55789 1/20 0.63

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL45299 1.00 ALDH1A1 (1.00) ALDH1A1CYP3A4CYP2C9ALOX12MEN1
SCHEMBL13927135 0.96 ALDH1A1 (0.92) ALDH1A1CYP3A4CYP2C9ALOX12MEN1
SCHEMBL437231 0.93 ALDH1A1 (0.87) ALDH1A1CYP3A4CYP2C9ALOX12MEN1
SCHEMBL12189649 0.92 ALDH1A1 (0.85) ALDH1A1CYP3A4CYP2C9ALOX12MEN1
SCHEMBL11266257 0.91 ALDH1A1 (0.83) ALDH1A1CYP3A4CYP2C9ALOX12MEN1
SCHEMBL11266259 0.91 ALDH1A1 (0.83) ALDH1A1CYP3A4CYP2C9ALOX12MEN1
SCHEMBL328588 0.91 ALDH1A1 (0.82) ALDH1A1CYP3A4CYP2C9ALOX12MEN1
SCHEMBL13927138 0.90 ALDH1A1 (0.81) ALDH1A1CYP3A4CYP2C9ALOX12MEN1
SCHEMBL1336628 0.88 ALDH1A1 (0.79) ALDH1A1CYP3A4CYP2C9ALOX12MEN1
SCHEMBL29360103 0.88 ALDH1A1 (0.79) ALDH1A1CYP3A4CYP2C9ALOX12MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140005049-A1 ACTIVE COMPOUND COMBINATIONS ILG KERSTIN (DE) 2014-01-02 US claimed
EP-2515649-A2 ACTIVE COMPOUND COMBINATIONS Bayer Intellectual Property GmbH (DE) 2012-10-31 EP claimed
WO-2011080044-A2 ACTIVE COMPOUND COMBINATIONS BAYER CROPSCIENCE AG (DE) 2011-07-07 WO claimed
US-20110152077-A1 Active compound combinations BAYER CROPSCIENCE AG (DE) 2011-06-23 US claimed
US-20140005049-A1 ACTIVE COMPOUND COMBINATIONS ILG KERSTIN (DE) 2014-01-02 US disclosed
US-20140007297-A1 BRASSICA PLANTS WITH ALTERED ARCHITECTURE BAYER CROPSCIENCE NV (BE) 2014-01-02 US disclosed
US-8530381-B2 Active compound combinations BAYER CROPSCIENCE AG (DE) 2013-09-10 US disclosed
EP-2566318-A1 BRASSICA PLANTS WITH ALTERED ARCHITECTURE Bayer CropScience NV (BE) 2013-03-13 EP disclosed
EP-2515649-A2 ACTIVE COMPOUND COMBINATIONS Bayer Intellectual Property GmbH (DE) 2012-10-31 EP disclosed
WO-2011137998-A1 BRASSICA PLANTS WITH ALTERED ARCHITECTURE BAYER BIOSCIENCE N.V. (BE) 2011-11-10 WO disclosed
WO-2011080044-A2 ACTIVE COMPOUND COMBINATIONS BAYER CROPSCIENCE AG (DE) 2011-07-07 WO disclosed
US-20110152077-A1 Active compound combinations BAYER CROPSCIENCE AG (DE) 2011-06-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110152077-A1 Active compound combinations BROX, ATL3, AKR7A2 ALDH1A1 3621/4885CYP3A4 1702/4885CYP2C9 696/4885
US-20140005049-A1 ACTIVE COMPOUND COMBINATIONS BROX, ATL3, AKR7A2 ALDH1A1 3621/4885CYP3A4 1702/4885CYP2C9 696/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.